Clinical Study
Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)
Table 3
Incidences of SAEs during the 18-month follow-up period (safety set).
| Preferred term, (%) | Unilateral DME () | Bilateral DME () |
| Any SAE | 7 (4.46) | 22 (4.84) | Cardiac disorders | 2 (1.27) | 6 (1.32) | Acute myocardial infarction | 0 | 1 (0.22) | Atrial flutter | 1 (0.64) | 0 | Cardiac arrest | 0 | 1 (0.22) | Cardiac failure | 0 | 3 (0.66) | Cardiopulmonary failure | 0 | 1 (0.22) | Congestive cardiomyopathy | 1 (0.64) | 0 | Ischemic cardiomyopathy | 0 | 1 (0.22) | Myocardial ischemia | 1 (0.64) | 0 | Eye disorders | 0 | 2 (0.44) | General disorders and administration site conditions | 0 | 1 (0.22) | Infections and infestations | 0 | 3 (0.66) | Injury, poisoning, and procedural complications | 0 | 2 (0.44) | Metabolism and nutrition disorders | 0 | 1 (0.22) | Musculoskeletal and connective tissue disorders | 0 | 1 (0.22) | Neoplasms benign, malignant, and unspecified (including cysts and polyps) | 1 (0.64) | 3 (0.66) | Nervous system disorders | 2 (1.27) | 3 (0.66) | Renal and urinary disorders | 1 (0.64) | 1 (0.22) | Respiratory, thoracic, and mediastinal disorders | 1 (0.64) | 1 (0.22) | Surgical and medical procedures | 0 | 1 (0.22) | Vascular disorders | 1 (0.64) | 1 (0.22) |
|
|
DME, diabetic macular edema; SAE, serious adverse event.
|